Plastic electronics to bring “mind-blowing” developments for pharma
February 14, 2017Manufacturing and Production, Research and Development plastic electronics
Plastic electronics could be the next big thing for pharma production and treatment , according to a new report on …
Hepatitis C market set for slump as cure rates rise
February 14, 2017Manufacturing and Production, Medical Communications, Sales and Marketing Gilead, hepatitis C
Objectively, it is the pharmaceutical industries intention to find cures for diseases and to aid patients to live a full …
GSK unveils strong showing for twin-drug HIV treatment
February 14, 2017Manufacturing and Production, Research and Development GSK, GlaxoSmithKline, HIV, Tivicay
GlaxoSmithKline has announced strong Phase 3 findings for its own Tivicay (dolutegravir) as part of a twin-drug regimen with J&J’s …
Marathon’s major misstep shows that drug pricing debate is here to stay
February 14, 2017Manufacturing and Production, Sales and Marketing Duchenne Muscular Dystrophy, Emflaza, marathon
Marathon Pharmaceuticals’ approval, last week, by the FDA for its treatment for Duchenne muscular dystrophy would usually have been cause …
Allergan set to bolster ‘medical aesthetics’ unit with $2.5 billion Zeltiq deal
February 13, 2017Manufacturing and Production, Sales and Marketing Allergan, FDA, Zeltiq
Allergan, the owner of Botox, has expanded its stake in the ‘medical aesthetics’ business by acquiring Zeltiq Aesthetics. Zeltiq has …
Pfizer and Flynn: How are ‘excessive’ prices for generic drugs possible and should competition authorities do more about exploitative pricing?
February 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, Pfizer, flynn
As last year came to a close, the headlines were rocked by the news that pharma giant Pfizer had been …
NICE turns down AZ’s chronic obstructive pulmonary disease drug
February 13, 2017Sales and Marketing AstraZeneca, Daxas, NICE, chronic obstructive pulmonary disease
AstraZeneca’s Daxas (roflumilast) has been knocked back in draft guidance by the National Institute for Health and Care Excellence (NICE), …
Lilly €200m expansion of Cork site under review
February 13, 2017Manufacturing and Production, Sales and Marketing Eli Lilly, Ireland, cork
Eli Lilly’s planned €200m investment to its manufacturing plant in Kindsdale, County Cork, is now under-review. The expansion would bring …
Ipsen to acquire Sanofi assets in $88 million deal
February 13, 2017Sales and Marketing Boehringer Ingelheim, Prontalgine, Sanofi, ipsen
Ipsen has announced that it is set to enter into a definitive agreement to acquire five consumer healthcare products from …
First-ever approved fertility app more effective than the pill, experts say
February 13, 2017Research and Development, Sales and Marketing contraception
Fertility app Natural Cycles has become the first-ever smartphone application and software solution to be approved by experts as a …
Seattle Genetics’ prospective $2 billion licensing deal not without controversy
February 13, 2017Sales and Marketing Immunomedics, Seattle Genetics, enVio
Immunomedics announced on 10 February that it had entered a licensing agreement with Seattle Genetics for its leading experimental cancer …
Teva’s Vigodman becomes third CEO to leave in 5 years
February 10, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva
Teva has maintained its habit of changing CEOs rather frequently, as Erez Vigodman has left by “mutual agreement”. He becomes …
Thomas Cueni named as new IFPMA Director General
February 10, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing IFPMA
Thomas Cueni has become the new Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and will …
Intelligent Fingerprinting secures £3 million funding for portable drug screening
February 10, 2017Medical Communications, Research and Development Intelligent Fingerprinting, drug testing, nanotechnology
Intelligent Fingerprinting has received a funding boost to market its fingerprint-based drug screening system further. It is the world’s first …
Top Ten most popular articles on Pharmafile.com this week
February 10, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biggest news, biggest stories, top 10, top 10 stories, top stories, top ten
Two of our top five stories this month are about one company in particular – a company that’s having a …
Vital Signs: Partnerships between industry, providers and academia
February 10, 2017Medical Communications Deloitte
Hanno Ronte, life sciences partner at Deloitte, writes upon the opportunities available when a collaborative environment between industry, providers and …
Brexit could delay key drugs to UK patients, ex-MHRA chairman claims
February 10, 2017Medical Communications, Sales and Marketing Cancer, MHRA, brexit
Former UK regulator and ex-chairman of the Medicines and Healthcare products Regulatory Agency (MHRA) Sir Alasdair Breckenridge has warned that …
FDA approves first treatment for Duchenne muscular dystrophy
February 10, 2017Medical Communications, Sales and Marketing Duchenne Muscular Dystrophy, FDA, marathon, marathon pharmaceuticals
The FDA has announced that it has approved Emflaza (deflazacort), developed by Marathon Pharmaceuticals. The treatment will arrive on the …
Three quarters of healthcare companies to invest in big data by 2021
February 9, 2017Medical Communications, Research and Development Big Data, analytics, clinical trials
The latest research by GBI Research suggests that there may be shift towards the use of big data and analytics …
Top five European countries by pharmaceutical spending per capita
February 9, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing European Pharmaceutical, pharmaceutical market, price
With pricing never far from the news and yet more news stories emerging around the inflated prices of certain generics …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
